Low urine pH associated with sarcopenia in the elderly
A multi-center observational study

Akihiro Saitsu, MDa, Yoshitaka Iwazu, MDPhDb, Haruka Matsushita, MDC, Hirotaka Hayashi, MDC, Yumiko Mizuhashi, MDD, Kazuhiko Kotani, MD, PhDa–c

Abstract
The pathophysiology of sarcopenia is complex and must be further explored. While metabolic acidosis may be a risk factor for sarcopenia, it remains unclear whether acidic urine is related to sarcopenia. The purpose of the present study was to investigate the association between sarcopenia and urine pH in the elderly.

An elderly population (n = 123 [male = 46]; mean age = 81.7 years) was classified into 2 groups based on the sarcopenia status according to their strength, requirement of assistance in walking, their ability to rise from a chair, their ability to climb stairs, and their history of falls. Urinalysis was measured using dipstick tests.

The sarcopenia group (n = 32) was significantly older, had less exercise habit and showed a lower urine pH (mean pH = 6.2, P < .01) in comparison to the nonsarcopenia group (mean pH = 6.5, P = .02). A multivariate analysis that was adjusted for age, male sex, body mass index, uro-renal variables and exercise habit revealed that urine pH (odds ratio, 0.43; 95% confidence interval, 0.22–0.85, P = .02), age and less exercise habit were independently and significantly associated with sarcopenia.

The findings of the present study suggest a potential association between metabolic acidosis and the pathophysiology of sarcopenia in the elderly. As urine pH is a simple biomarker that can be obtained using dipstick tests, it is therefore expected to be helpful for detecting sarcopenia in the clinical setting.

Abbreviations: BMI = body mass index, GFR = glomerular filtration rate, SARC-F = strength, assistance in walking, rising from a chair, climbing stairs, and falls.

Keywords: aciduria, aging, rural district, sarcopenia, urine dipstick test

1. Introduction
Sarcopenia is the age-related loss of muscle mass, strength, and/or performance.[1–3] The prevalence of sarcopenia in the elderly is high (10%–50%).[4–7] With aging trends worldwide, the population of individuals with sarcopenia is rapidly increasing. Sarcopenia is thus a serious public issue as it is associated with an increased risk of falls and fractures,[8] reduced activities of daily living,[9] reduced quality of life,[10] and increased mortality.[11]

The aging process is characterized by a progressive decline in the intrinsic physiologic function of all organs.[12] For instance, the kidney is one of the best organs related to aging, and a reduced glomerular filtration rate (GFR) with albuminuria and/or proteinuria is suggested to the presence of sarcopenia even in the population without chronic kidney disease.[13,14] The early detection of such an aging process is important; however, this is so difficult in individuals with sarcopenia due to its asymptomatic situations and a lack of easily measured biomarkers.[15]

Of interest, previous studies have demonstrated that chronic kidney diseases,[16,17] chronic heart failure,[18] and metabolic abnormalities such as obesity and metabolic syndrome[19,20] can show a low level of urine pH. Additionally, these diseases and syndromes were indicated to be associated with aging and sarcopenia.[21,22] Given the phenomenon, the relationship between metabolic acidosis and biological aging may be hypothesized.[23] The pathophysiology of sarcopenia is complex and must still be explored, while urine pH may be related to the presence of sarcopenic conditions. The present study therefore aimed to investigate the association between sarcopenia and urine pH easily measured using urine dipstick tests.
2. Methods

2.1. Study population

A multicenter, cross-sectional study was conducted from August 2018 to February 2019 in the patients with common diseases who attended 3 clinics in Japan. A total of 123 patients (mean age, 81.7 years) were interviewed to investigate their strength, requirement for assistance in walking, ability to rise from a chair, ability to climb stairs, and history falls using strength, assistance in walking, rising from a chair, climbing stairs, and falls (SARC-F). which is a screening tool for sarcopenia. The following exclusion criteria were applied: subjects without sufficient urinalysis, with <70 years of age, and with serum creatinine >2.0 mg/dL meaning kidney dysfunction. The present study protocol was approved by the institutional Ethics Committee of Jichi Medical University (approval number: 18–149). The study was conducted in accordance with the Helsinki Declaration.

2.2. Assessment of sarcopenia

The SARC-F has 5 items that assess the patient’s perception of their limitations in strength, ability to walk, rise from a chair, and climb stairs, and their experience of falls. The scores range from 0 to 10 (0 indicating the best result and 10 indicating the worst result). The patients were classified, according to these scores, into the nonsarcopenia (0–3 points) group and the sarcopenia (≥4 points) group.

2.3. Clinical and laboratory variables

Clinical information, such as the existence of hypertension, diabetes mellitus, and hyperlipidemia, was simultaneously obtained. The information of exercise habit (≥1 time per week regularly) was also obtained on self-report. The body mass index (BMI) was calculated as the weight in kilograms divided by height in meters squared. After an overnight fast, venous blood was collected for the measurement of serum creatinine. The GFR was estimated using the Japanese Society of Nephrology equation: estimated GFR = $194 \times \text{serum-creatinine}^{-0.94} \times \text{age}^{-0.287}$ (mL/min/1.73 m²). For women, the estimated GFR was multiplied by a correction factor of 0.739. Urine pH, proteinuria, occult blood and glycosuria were determined in fasting morning urine using standardized dipstick tests. Urine pH is typically measured with a reagent test strip in which methyl red and bromothymol blue for a range of colors at different pH values. In dipping the strip into the spot urine obtained from midstream urine, pH based on the colors is judged in 30 to 60 seconds.

2.4. Statistical analyses

Data were expressed as the mean and standard deviation for continuous variables, and proportions were used for categorical variables. Comparisons were made between 2 groups using the Chi-Squared test for categorical variables and the t test for continuous variables. We used a multiple logistic regression analysis adjusted for measured variables (selected to avoid an over-adjustment). Data were analyzed using IBM SPSS, Version 25.0 (Tokyo, Japan). In all analyses, P values of <.05 were considered a statistical significance.

3. Results

As shown in Table 1, all patients were divided, based onto the results of SARC-F, into the non-sarcopenia group (n = 91) and the sarcopenia group (n = 32). The patients in the sarcopenia group were significantly older than those in the nonsarcopenia group. There were significantly less exercise habit in the sarcopenia than in the nonsarcopenia group. There were no significant differences in sex, BMI, estimated GFR, or hypertension, diabetes mellitus, and hyperlipidemia between the sarcopenia and non-sarcopenia groups. The urine pH levels of the sarcopenia group were significantly lower in comparison to the nonsarcopenia group. There were no marked differences between the groups in the proportion of proteinuria, occult blood, and glycosuria.

The factors associated with sarcopenia are shown in Table 2. Low pH levels, older age, and less exercise habit were significantly associated with sarcopenia. After adjustment for age, male sex, BMI, serum creatinine, urine pH, proteinuria, occult blood, glycosuria and exercise habit, urine pH (odds ratio, 2.4. Statistical analyses

Data were expressed as the mean and standard deviation for continuous variables, and proportions were used for categorical variables. Comparisons were made between 2 groups using the Chi-Squared test for categorical variables and the t test for continuous variables. We used a multiple logistic regression analysis adjusted for measured variables (selected to avoid an over-adjustment). Data were analyzed using IBM SPSS, Version 25.0 (Tokyo, Japan). In all analyses, P values of <.05 were considered a statistical significance.

3. Results

As shown in Table 1, all patients were divided, based onto the results of SARC-F, into the non-sarcopenia group (n = 91) and the sarcopenia group (n = 32). The patients in the sarcopenia group were significantly older than those in the nonsarcopenia group. There were significantly less exercise habit in the sarcopenia than in the nonsarcopenia group. There were no significant differences in sex, BMI, estimated GFR, or hypertension, diabetes mellitus, and hyperlipidemia between the sarcopenia and non-sarcopenia groups. The urine pH levels of the sarcopenia group were significantly lower in comparison to the nonsarcopenia group. There were no marked differences between the groups in the proportion of proteinuria, occult blood, and glycosuria.

The factors associated with sarcopenia are shown in Table 2. Low pH levels, older age, and less exercise habit were significantly associated with sarcopenia. After adjustment for age, male sex, BMI, serum creatinine, urine pH, proteinuria, occult blood, glycosuria and exercise habit, urine pH (odds ratio, 2.4. Statistical analyses

Data were expressed as the mean and standard deviation for continuous variables, and proportions were used for categorical variables. Comparisons were made between 2 groups using the Chi-Squared test for categorical variables and the t test for continuous variables. We used a multiple logistic regression analysis adjusted for measured variables (selected to avoid an over-adjustment). Data were analyzed using IBM SPSS, Version 25.0 (Tokyo, Japan). In all analyses, P values of <.05 were considered a statistical significance.

3. Results

As shown in Table 1, all patients were divided, based onto the results of SARC-F, into the non-sarcopenia group (n = 91) and the sarcopenia group (n = 32). The patients in the sarcopenia group were significantly older than those in the nonsarcopenia group. There were significantly less exercise habit in the sarcopenia than in the nonsarcopenia group. There were no significant differences in sex, BMI, estimated GFR, or hypertension, diabetes mellitus, and hyperlipidemia between the sarcopenia and non-sarcopenia groups. The urine pH levels of the sarcopenia group were significantly lower in comparison to the nonsarcopenia group. There were no marked differences between the groups in the proportion of proteinuria, occult blood, and glycosuria.

The factors associated with sarcopenia are shown in Table 2. Low pH levels, older age, and less exercise habit were significantly associated with sarcopenia. After adjustment for age, male sex, BMI, serum creatinine, urine pH, proteinuria, occult blood, glycosuria and exercise habit, urine pH (odds ratio,
The decline of muscle mass, with the use of nitrogen as a buffer. $P = 0.87$, broken down to provide nitrogen and then the excretion of nitrogen, with the development of acidosis. Also, additional sarcopenic conditions of muscle declines are hard to provide. This induces a negative balance of protein by blunting synthesis of protein as well as degradation of protein, which presents the decline of muscle mass, with the use of nitrogen as a buffer. Metabolic acidosis consumes ammonia (NH$_3$), which contains nitrogen, and the conversion to ammonium (NH$_4^+$) alleviates the acidosis by accepting H$^+$ ions. In this process, the muscles are broken down to provide nitrogen and then the excretion of nitrogen to the urine increases, leading to aciduria. Since sarcopenic conditions of muscle declines are hard to provide nitrogen, with the development of acidosis. Also, additional evidence exists; for instance, a potassium bicarbonate supplementation revises metabolic acidosis, while alkali supplementation serves a nitrogen-sparing role and can protect muscle declines. These may partly explain aciduria, low pH, in patients with sarcopenia, as was observed in the present study.

An aged society is in progress worldwide and is facing a serious problem due to the increase in patients with sarcopenia. Thus, there is a need for objective biomarkers that can be easily applied in the detection of sarcopenia. As demonstrated in the present study, the use of urine dipstick tests, a simple method, appears to be effective. Dipstick test strips are reported to produce reliable results when the data are compared to data obtained using electrochemical pH meters. The strength of the present study was that it was conducted in multiple centers. Nevertheless, this study was associated with several limitations. First, the number of patients with sarcopenia was relatively small. Second, since the study was based on the cross-sectional design in nature, it is insufficient to mention any causality. The change of urine pH should be further examined by not only pharmacological interventions but also non-pharmacological treatments including exercise (even at a low-intensity resistance level). Third, exercise habit was self-reported and the report did not include the intensity and duration of exercise. Finally, we used the SARC-F to define sarcopenia. The European Working Group on sarcopenia in Older People recommends the measurement of muscle mass, strength, and performance for the diagnosis of sarcopenia while the SARC-F is considered to be adequately correlated with sarcopenia. These limitations to confirmation of the study findings will be addressed in future research.

### 5. Conclusions

The present study showed a significant association between lower urine pH and sarcopenia in the elderly, which might provide a new insight into the pathophysiology of sarcopenia. Urine pH is able to be measured using urine dipstick tests, which are available everywhere; accordingly, this might be useful for the early detection of sarcopenia in the clinical setting. The present study findings should be validated in further studies.

### Author contributions

Conceptualization: Akihiro Saitsu, Kazuhiko Kotani. Data curation: Akihiro Saitsu, Haruka Matsushita, Hirotaka Hayashi, Yumiko Mizuhashi. Formal analysis: Akihiro Saitsu. Funding acquisition: Kazuhiko Kotani. Investigation: Akihiro Saitsu, Yoshihata Iwazu, Haruka Matsushita, Hirotaka Hayashi, Yumiko Mizuhashi. Methodology: Yoshihata Iwazu, Haruka Matsushita, Hirotaka Hayashi, Yumiko Mizuhashi. Supervision: Kazuhiko Kotani. Writing – original draft: Akihiro Saitsu. Writing – review & editing: Yoshihata Iwazu, Kazuhiko Kotani.

### References

[1] Budui SL, Rossi AP, Zamboni M. The pathogenetic bases of sarcopenia. Clin Cases Miner Bone Metab 2015;12:22-6.
[2] Morley JE, Baumgartner RN, Roubenoff R, et al. Sarcopenia. J Lab Clin Med 2001;137:231–43.
[3] Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: facts, numbers, and epidemiology-update 2014. J Diabetes Metab Disord 2017;16:21.
[4] Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, 1; and epidemiology-update 2014. J Cachexia Sarcopenia Muscle 2014;5:253–9.
[5] von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010;1:129–33.
[6] Morley JE. Sarcopenia in the elderly. Fam Pract 2012;29 Suppl 1:44–8.
[7] Bischoff-Ferrari HA, Orav JE, Kanis JA, et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int 2015;26:2793–802.

---

### Table 2

| Factors associated with sarcopenia. | Crude OR | Adjusted OR |
|------------------------------------|----------|-------------|
| Variables                          | (95% CI) | P value     |
| Age                                | 1.21 (1.11–1.32) | P < .01 |
| Male sex                           | 0.57 (0.24–1.37) | P = 0.21 |
| Body mass index                    | 0.97 (0.87–1.09) | P = 0.01 |
| Serum creatinine                   | 1.17 (0.25–5.50) | P = 0.87 |
| Urine pH                           | 0.39 (0.22–0.70) | P < .01 |
| Proteinuria                        | 1.71 (0.76–3.86) | P = 0.25 |
| Occult blood                       | 1.02 (0.45–2.28) | P = 0.97 |
| Glycosuria                         | 1.47 (0.34–6.24) | P = 1.32 |
| Exercise habit                     | 0.38 (0.16–0.87) | P = 0.02 |

CI = confidence interval, OR = odds ratio.
[9] Malmstrom TK, Miller DK, Simonsick EM, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016;7:28–36.
[10] Beaudart C, Biver E, Reginster JY, et al. Validation of the SarQoL, a specific health-related quality of life questionnaire for sarcopenia. J Cachexia Sarcopenia Muscle 2017;8:238–44.
[11] Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019;393:2636–46.
[12] Flatt T. A new definition of aging? Front Genet 2012;3:148.
[13] Foley RN, Wang C, Ishani A, et al. Kidney function and sarcopenia in the United States general population: NHANES III. Am J Nephrol 2007;27:279–86.
[14] Hwang D, Cho MR, Choi M, et al. Association between sarcopenia and dipstick proteinuria in the elderly population: the Korea national health and nutrition examination surveys 2009–2011. Korean J Fam Med 2017;38:372–9.
[15] Cesari M, Fielding RA, Pahor M, et al. Biomarkers of sarcopenia in clinical trials-recommendations from the international working group on sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:181–90.
[16] Nakanishi N, Fukui M, Tanaka M, et al. Low urine pH is a predictor of chronic kidney disease. Kidney Blood Press Res 2012;35:77–81.
[17] Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Physiol 1992;263(4 Pt 1):F735–9.
[18] Nakanishi N, Fukui M, Tanaka M, et al. Low urine pH is a predictor of chronic kidney disease. Kidney Blood Press Res 2012;35:77–81.
[19] Shimodaira M, Okaniwa S, Nakayama T. Fasting single-spot urine pH is a predictor of metabolic syndrome: a retrospective cohort study in a Japanese urban population. Metabolism 2012;61:281–8.
[20] Otaki Y, Watanabe T, Takahashi H, et al. Acidic urine is associated with poor prognosis in patients with chronic heart failure. Heart Vessels 2013;28:735–41.
[21] Shimodaira M, Okaniwa S, Nakayama T. Fasting single-spot urine pH is associated with metabolic syndrome in the Japanese population. Med Princ Pract 2017;26:433–7.
[22] Har a S, Tsuji H, Ohmoto Y, et al. High serum uric acid level and low urine pH as predictors of metabolic syndrome: a retrospective cohort study in a Japanese urban population. Metabolism 2012;61:281–8.
[23] Yoshida T, Delafontaine P. Mechanisms of cachexia in chronic disease states. Am J Med Sci 2015;350:250–6.
[24] Zhang H, Lin S, Gao T, et al. Association between sarcopenia and metabolic syndrome in middle-aged and older nonobese adults: a systematic review and meta-analysis. Nutrients 2018;10:364.
[25] Frassetto L, Sebastian A. Age and systemic acid-base equilibrium: analysis of published data. J Gerontol A Biol Sci Med Sci 1996;51:B91–9.
[26] Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14:531–2.
[27] Okamura T, Hashimoto Y, Hamaguchi M, et al. Low urine pH is a risk for non-alcoholic fatty liver disease: a population-based longitudinal study. Clin Res Hepatol Gastroenterol 2018;42:570–6.
[28] Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92.
[29] Maarten WT, Glenn MC, Philip AM, et al. Brenner and Rector’s the kidney. 9th edn. PA: Saunders; 2011. 881.
[30] Casuso RA, Huertas JR. The emerging role of skeletal muscle mitochondrial dynamics in exercise and ageing. Ageing Res Rev 2020;58:101025.
[31] Beckwée D, Delaere A, Aelbrecht S, et al. Exercise interventions for the prevention and treatment of sarcopenia. a systematic umbrella review. J Nutr Health Aging 2019;23:494–502.
[32] Caso G, Garlick PJ. Control of muscle protein kinetics by acid-base balance. Curr Opin Clin Nutr Metab Care 2005;8:73–6.
[33] Reaich D, Shannon SM, Scrimgeour CM, et al. Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 1992;263(4 Pt 1):E735–9.
[34] Ballmer PE, McNurlan MA, Hulter HN, et al. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 1995;95:39–45.
[35] Ceglia L, Rivas DA, Pojednic RM, et al. Effects of alkali supplementation and vitamin d insufficiency on rat skeletal muscle. Endocrine 2013;44:454–64.
[36] Guder WG, Haussinger D, Gerok W. Renal and hepatic nitrogen metabolism in systemic acid base regulation. J Clin Chem Clin Biochem 1987;25:457–66.
[37] Waters DL, Mullins PG, Qualls CR, et al. Mitochondrial function in physically active elders with sarcopenia. Mech Ageing Dev 2009;130:315–9.
[38] Ceglia L, Dawson-Hughes B. Increasing alkali supplementation decreases urinary nitrogen excretion when adjusted for same day nitrogen intake. Osteoporos Int 2017;28:3355–9.
[39] Margolis LM, Ceglia L, Rivas DA, et al. Pilot study examining the influence of potassium bicarbonate supplementation on nitrogen balance and whole-body ammonia and urea turnover following short-term energy restriction in older men. Nutrients 2018;10:624.
[40] Welch AA, MacGregor AJ, Skinner J, et al. A higher alkaline dietary load is associated with greater indexes of skeletal muscle mass in women. Osteoporos Int 2013;24:1899–908.
[41] Desai RA, Assimos DG. Accuracy of urinary dipstick testing for pH manipulation therapy. J Endourol 2008;22:1367–70.
[42] Kera T, Kawai H, Hirano H, et al. SARC-F: a validation study with community-dwelling older Japanese adults. Geriatr Gerontol Int 2019;19:1172–8.